SCHOLAR ROCK HOLDING CORPORATION Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $120.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-03
- SCHOLAR ROCK HOLDING CORPORATION valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $120.00M, a 56.86% increase from fiscal 2024.
- SCHOLAR ROCK HOLDING CORPORATION valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $76.50M, a 55.49% increase from fiscal 2023.
- SCHOLAR ROCK HOLDING CORPORATION valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $49.20M, a 14.42% increase from fiscal 2022.
- SCHOLAR ROCK HOLDING CORPORATION valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $43.00M, a 1.65% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $120.00M 10-K · filed 2026-03-03 |
| 2024-12-31 | $76.50M 10-K · filed 2026-03-03 |
| 2023-12-31 | $49.20M 10-K · filed 2025-02-27 |
| 2022-12-31 | $43.00M 10-K · filed 2024-03-19 |
| 2021-12-31 | $42.30M 10-K · filed 2023-03-07 |
| 2020-12-31 | $29.70M 10-K · filed 2022-03-07 |
| 2019-12-31 | $17.30M 10-K · filed 2021-03-09 |
| 2018-12-31 | $19.20M 10-K · filed 2020-03-12 |
| 2017-12-31 | $4.00M 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |